A Phase III Trial to Evaluate RV001 in Prostate Cancer
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Onilcamotide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Feb 2023 According to a CHOSA Oncology media release, RhoVac AB changes name to CHOSA Oncology AB.
- 05 Dec 2019 New trial record
- 02 Dec 2019 According to a RhoVac media release, the company aims to to secure an agreement with a partner that can further develop the RV001 project for this clinical phase III trial in prostate cancer.